Header search > ticker > Open Stock TerminalSelect the market and trading date first when you need a specific listing or historical session.
TradingFloor AI · Stock TerminalBMRN - Ticker AI Digest
Biomarin Pharmaceutical Inc 📰 1
64.66500000
| Today -0.96%
●
Important AI Risk Notice
Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.
Not investment advice.
Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate.
Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only.
Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally.
Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Biomarin Pharmaceutical Inc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
BMRN
Data 2026-08-31
Preview Mode
Core Deck
Deep Dive Modules
Digested News
Today's Catalysts (BMRN) 1
BMRN
14:47
Biomarin Pharmaceutical Inc
AI 0
Acquisitions 0
Admission 0
Agreement 0
Approvals 0
Authorisation 0
Awards 0
BTC 0
BlockListing 0
Blockchain 0
Breakthrough 0
BuyBack 0
Cancellations 0
CashOffer 0
Circular 0
ClinicalTrial 0
Collaborate 0
ContractWin 1
BMRN
05:08
Biomarin Pharmaceutical Inc
Covid-19 0
Deals 0
Diamond 0
DirectorDealing 0
DirectorateChange 0
Discovery 0
Dividend 0
Exceeded 0
FCA 0
FDA 0
Form83 0
GeneralMeeting 0
Grants 0
InvestmentPlan 0
IssueOfEquity 0
JV 0
Launch 0
Litigation 0
MonthlyFactsheet 0
NAV 0
NameChange 0
NewContract 0
Offers 0
Offtake 0
Orders 0
OwnShares 0
Partner 0
Patents 0
Placing 0
Positive 0
ProfitWarning 0
Proposals 0
Prospectus 0
Reports 1
BMRN
14:30
Biomarin Pharmaceutical Inc
Results 1
BMRN
12:05
Biomarin Pharmaceutical Inc
SchemeOfArrangement 0
Significant 0
Speculation 0
Strategic 0
Suspension 0
TR1 0
TVR 0
Takeover 0
US News 0
Understanding 0
Updates 0
Vaccine 0
Wins 0
Worth 1
All Market News (Last 30 Days) 13
BMRN
14:47
Biomarin Pharmaceutical Inc
BMRN
13:48
Biomarin Pharmaceutical Inc
BMRN
14:37
Biomarin Pharmaceutical Inc
BMRN
11:45
Biomarin Pharmaceutical Inc
BMRN
17:55
Biomarin Pharmaceutical Inc
BMRN
12:05
Biomarin Pharmaceutical Inc
BMRN
09:47
Biomarin Pharmaceutical Inc
BMRN
05:08
Biomarin Pharmaceutical Inc
BMRN
14:30
Biomarin Pharmaceutical Inc
Today's AI
BMRN · Agentic Market Intelligence
BMRN intelligence is listening.
The engine is monitoring news, price structure, forecasts and financial changes. New scored evidence will appear here against this stock automatically.
AI bias0.0
Bullish0
Bearish0
Today's AI Starts With News
1 live catalyst is opening Today’s AI for BMRN.
Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape
Data 2026-08-31
Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1
Today
Front Of Desk
Biomarin Pharmaceutical Inc has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
BMRN signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.
This is the ticker-specific Today’s AI desk for Biomarin Pharmaceutical Inc. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.
Subscription Required
Bullish vs Bearish Scoring
AI + Financial Blend
Buy / Sell Trigger Engine
Today's AI Findings
Subscriber Unlock
Subscribe to unlock the full BMRN Today’s AI cockpit.
Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.
- AI-scored market headlines with sentiment buckets and buzzword breakdowns.
- Forecast leaders ranked by projected gain against current market price.
- Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
- Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
- Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
- Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for BMRN on 2026-08-31.
Fundamentals Matrix
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
11.4B
Enterprise Value
10.6B
Public Float
99.4
Broker Target
87.8462
Shares Out
193.3M
Long Interest
97
Short Interest
3
Exchange
NASDAQ
Currency Code
USD
ISIN
US09061G1013
Ex-Dividend
-
Yield
0.00%
Dividend Rate
-
EPS
1.39
Market
NASDAQ
Standard Lists
Not currently ranked
Sector
Software and Computer ServicesUS fundamentals
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-
Financials Matrix
News And Alerts First
1 live alert now opens the financials desk for BMRN.
Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts
Data 2026-08-31
Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1
Alerts
Front Of Desk
Biomarin Pharmaceutical Inc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
-
Earnings Date
-
Net Debt
-668.8M
Cash
1.3B
EPS
1.39
Net Income
348.9M
Revenue
3.2B
Enterprise Value
10.6B
Trailing PE
42.4389
Forward PE
11.8483
Price Sales TTM
3.5166
Price Book MRQ
1.8357
EV Revenue
3.2757
EV EBITDA
22.0129
Financial Forecastist
Worsening financial engine
Revenue is accelerating +2.8% against the prior comparable period. Net margin is compressing by 11.1 pts. Net debt is building +75.2%.
Revenue +2.8%
Net Income -43.2%
FCF +26.7%
Current Ratio 5.81x
Forward Rev 1.1B
Worsening
Quarter Revenue
766.2M
+2.8%
vs prior comparable quarter
Net Margin
+13.8%
-11.1 pts
profitability pulse
Free Cash Flow
199.7M
+26.7%
cash conversion
Net Debt / EBITDA
-4.5x
+75.2%
lower is cleaner
Revenue Engine
Latest quarter printed 766.2M with the top line pushing higher against the last comparable period.
Profit Stack
Net income landed at 105.5M and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.
Balance-Sheet Pressure
Cash sits near 2.2B while net debt is -782.8M. The leverage stack is moving the wrong way.
Quarterly Revenue Runway
Actual revenue bars, consensus revenue where available, plus the terminal model path.
Profit And Cash Conversion
Net income and free cash flow moving together is usually what separates genuine improvement from noise.
Balance-Sheet Pressure
Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.
Annual Power Curve
Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2025
Consensus
780.2M
Revenue Path
0.32
EPS / Earnings
Growth cue -0.6%
Q1 2026
Consensus
751.7M
Revenue Path
0.91
EPS / Earnings
Growth cue -0.2%
Q2 2026
Consensus
933.5M
Revenue Path
0.96
EPS / Earnings
Growth cue -0.3%
Q3 2026
Consensus
1.1B
Revenue Path
1.49
EPS / Earnings
Growth cue +11.4%
FY 2026
Consensus
3.9B
Revenue Path
4.94
EPS / Earnings
Growth cue +0.6%
FY 2027
Consensus
4.5B
Revenue Path
6.46
EPS / Earnings
Growth cue +0.3%
Quarterly Statement Tape
Last 6 Quarters
| Period | Revenue | Net Income | FCF | Net Debt |
|---|---|---|---|---|
| Q1 2026 | 766.2M | 105.5M | 199.7M | -782.8M |
| Q4 2025 | 874.6M | -46.6M | 58.9M | -668.8M |
| Q3 2025 | 776.1M | -30.7M | 340.2M | -645.9M |
| Q2 2025 | 825.4M | 240.5M | 168.2M | -610.0M |
| Q1 2025 | 745.1M | 185.7M | 157.6M | -446.8M |
| Q4 2024 | 747.3M | 124.9M | 165.3M | -340.1M |
Annual Financial Power
Last 5 Years
| Period | Revenue | Net Income | EBITDA | FCF |
|---|---|---|---|---|
| FY 2025 | 3.2B | 348.9M | 572.9M | 725.0M |
| FY 2024 | 2.9B | 426.9M | 650.5M | 475.4M |
| FY 2023 | 2.4B | 167.6M | 306.8M | 51.6M |
| FY 2022 | 2.1B | 141.6M | 265.4M | 54.9M |
| FY 2021 | 1.8B | -64.1M | 47.4M | 185.3M |
Structure DNA
Market Structure DNA
Balanced Structure profile with trend mixed
Price is 57.2% through the 52-week range, +7.8% vs 50DMA and +5.8% vs 200DMA. 100.0% of the register is locked by institutions and insiders, leaving 0.0% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.
Trend mixed
Institutional gravity
Moderate income rhythm
As Of 2026-07-06
Balanced Structure
Structure Score
62.2 / 100
Balanced Structure
Trend Stack
+7.8% / +5.8%
vs 50DMA / 200DMA
52W Position
57.2%
auction position inside the yearly range
Ownership Lock
100.0%
102.3% institutions | 34.6% insiders
Pressure Pocket
6.5% short float
Short ratio 5.1x | monthly +7.9%
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway
Implied spot is 58.99 with the stock +7.8% vs 50DMA and +5.8% vs 200DMA. The tape is sitting 57.2% through the 52-week range, which frames the regime as trend mixed.
Ownership Register
Institutions hold about 102.3% and insiders about 34.6%, locking roughly 100.0% of the register and leaving 0.0% in free float. That reads as institutional gravity.
Pressure Pocket
Short pressure is running near 6.5% of float with short ratio 5.1x and monthly change +7.9%. That gives us a read on whether the tape is clean, crowded, or coiled.
Capital Rhythm
Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.
Structure Score
One-glance gauge for the current market-structure regime.
Pillar Radar
Trend, ownership, pressure, and capital rhythm mapped on one wheel.
Position And Float Balance
Shows whether the stock is extended, tightly held, or carrying capital-return support.
Dividend Cadence Tape
Historical dividend-event counts help reveal how dependable the income rhythm has been.
Dividend Cadence Ledger
No cadence
| Year | Dividend Count | Context |
|---|---|---|
| Dividend history has not been normalized yet. | ||
Structure Facts
Live Snapshot
Implied Spot
58.99
derived from market cap / shares
52W High
66.28
upper auction edge
52W Low
49.26
lower auction edge
Beta
0.24
volatility character
Shares Out
193.3M
fully diluted count
Shares Float
192.1M
tradable register
Shares Short
12.5M
borrowed stock
Short Ratio
5.1x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied
Capital Radar
Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
106.8855
Institutions As Of
2026-05-31
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
40
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder
Short Data · BMRN · Last 30 Days
Short D · 12/26 EMA spread with 9 signal
Red histogram bars show short loading accelerating. Green bars show short covering accelerating. The two lines expose the crossover before the raw holder table does.
Short D waiting
Building BMRN short-momentum read
Short D compares the ticker’s disclosed short-position momentum with its own signal line.
Short D—
Signal—
Momentum—
Declared Short Holders
Nexus Pulse Engine
Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending
Volatility Lab
ATR(14)
Realized Vol (20d)
Volume Spike Z
AI Charts
News And Alerts First
The alert tape opens the door for BMRN, and AI Charts sits just below.
Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape
Data 2026-08-31
AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1
Today
Catalyst Pulse
Biomarin Pharmaceutical Inc has fresh news flow live now, so the tape is framing the chart workspace below.
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.
Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.
Automated Signalling
Automated AI Forecasts
Predictive MACD
Catalyst Beacons
Live Price Structure
AI AutoDetection
Automatic bull / bear chart read
Detected market structure
Analysing selected range
Why this call
Waiting for sufficient price history.
Invalidation
—
Updates with the timeframe.
Bull caseCalculating upside confirmation.
Bear caseCalculating downside confirmation.
RSI Gauge
Price Change
AI Forecast